<DOC>
	<DOCNO>NCT00382837</DOCNO>
	<brief_summary>Epratuzumab investigational antibody design help treat SLE . The purpose evaluate safety long term efficacy concert standard SLE treatment</brief_summary>
	<brief_title>Study Epratuzumab Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Must complete SL0003 Alleviate A 48 week Development toxicity Epratuzumab Significant protocol deviation SL0003 Study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Lupus ,</keyword>
	<keyword>Antibody ,</keyword>
	<keyword>B-Cell immunotherapy</keyword>
</DOC>